Jardiance EMA vs FDA: What the Label Differences Mean for Women

What Jardiance Is and Why the Regulator Differences Matter to You

Jardiance is an SGLT2 inhibitor, a class of oral drugs that block glucose reabsorption in the kidney and cause excess sugar to be excreted in urine. Its generic name is empagliflozin. Originally developed for type 2 diabetes, it has since received expanded indications for heart failure and chronic kidney disease from both the U.S. Food and Drug Administration and the European Medicines Agency, though the exact wording, scope, and post-market obligations differ between the two agencies.

Those differences are not just regulatory paperwork. They determine which patients a clinician can prescribe Jardiance for on-label, what monitoring is required, and which safety language appears on the package insert your pharmacist sees. For women, who metabolize SGLT2 inhibitors differently and carry a higher absolute risk of genital mycotic infections on this drug class, the label is a living document that shapes real-world care.

A Brief History of the Two Approvals

The EMA granted its first marketing authorization on May 22, 2014, and the FDA followed on August 1, 2014, both initially for glycemic control in adults with type 2 diabetes. The timelines were close, but the supporting data packages and post-approval commitments were negotiated separately, leading to divergent label evolution over the following decade.

The FDA's label has been updated multiple times since 2014, most consequentially in 2016 after EMPA-REG OUTCOME, in 2021 for heart failure with reduced ejection fraction, and in 2023 for chronic kidney disease. The EMA's European Public Assessment Report (EPAR) tracks a parallel but not identical arc.

Why Two Labels Can Say Different Things

The FDA uses a single prescribing information document anchored in U.S. Regulatory statute. The EMA uses a Summary of Product Characteristics (SmPC) that applies across EU member states. The two documents use different formats, different risk-communication conventions, and different thresholds for how prominently a warning must appear. Neither label is automatically updated when the other changes.

The EMPA-REG OUTCOME Trial and How Each Agency Interpreted It

EMPA-REG OUTCOME is the trial that changed empagliflozin from a glucose-lowering pill into a cardiovascular medication. Published in the New England England Journal of Medicine in 2015, the trial enrolled 7,020 adults with type 2 diabetes and established cardiovascular disease and showed a 38% relative risk reduction in cardiovascular death with empagliflozin 10 mg or 25 mg versus placebo over a median follow-up of 3.1 years. Hospitalization for heart failure fell by 35% relative to placebo in the same dataset.

What the FDA Did With This Data

The FDA accepted a supplemental NDA and in December 2016 added language to the U.S. Prescribing information stating that Jardiance is indicated "to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease." This was the first cardiovascular outcome indication for any SGLT2 inhibitor approved by the FDA. The agency also required Boehringer Ingelheim to conduct post-market studies through the FDA Sentinel System, which monitors real-world safety signals in U.S. Insurance claims data.

What the EMA Did With This Data

The EMA updated the SmPC to include cardiovascular benefit language, but framed it within the broader context of "treatment of adults with type 2 diabetes mellitus" rather than creating a standalone cardiovascular mortality indication in the same sharp language the FDA used. The EMA's EPAR product information notes that empagliflozin "reduces the risk of CV death" but integrates this within the glucose-lowering section rather than elevating it to a co-primary indication in the way the U.S. Label reads.

This framing difference is subtle, but it matters for insurance reimbursement, prescribing authority, and how primary care clinicians communicate benefit to patients.

The Women's Data Problem Inside EMPA-REG OUTCOME

Here is the piece of information that most published summaries skip: women made up only 28.5% of the EMPA-REG OUTCOME trial population. Neither the FDA label nor the EMA SmPC explicitly flags this underrepresentation, and neither agency required sex-stratified primary efficacy analyses as a condition of approval. The subgroup data that does exist suggests the cardiovascular mortality benefit may be directionally consistent in women, but the confidence intervals in the female subgroup are wide enough that you cannot conclude with statistical certainty that the 38% relative risk reduction applies equally to women. Both labels present the overall result without this caveat prominently displayed.

This is an evidence gap that matters to you if you are a woman with type 2 diabetes and cardiovascular disease deciding whether the cardiovascular mortality benefit that your doctor cites actually applies to your biology.

FDA vs EMA on Heart Failure and Kidney Disease Indications

Heart Failure With Reduced Ejection Fraction

In August 2021, the FDA approved empagliflozin 10 mg for heart failure with reduced ejection fraction (HFrEF) based on the EMPEROR-Reduced trial, regardless of whether the patient had diabetes. The EMA followed with a similar indication. Both agencies relied on the same primary trial data, but the FDA label is more explicit about the "regardless of diabetes status" wording.

Heart Failure With Preserved Ejection Fraction

The EMPEROR-Preserved trial, published in the New England Journal of Medicine in 2021, showed that empagliflozin reduced the composite of CV death or hospitalization for heart failure by 21% relative risk reduction in patients with HFpEF. The FDA expanded the label to include HFpEF in 2022. This is clinically significant for women because HFpEF is more prevalent in women than in men, particularly after menopause, when estrogen withdrawal accelerates left ventricular stiffening and diastolic dysfunction.

Chronic Kidney Disease

In 2023, the FDA approved empagliflozin for chronic kidney disease (CKD) based on the EMPA-KIDNEY trial, extending the indication to patients with eGFR as low as 20 mL/min/1.73 m2. The EMA has also added CKD language to the SmPC, though with slightly different eGFR thresholds and monitoring requirements.

Life-Stage Guide: Who Is This Drug For, Across a Woman's Life

Reproductive Years (Ages 18-40, Not Pregnant)

Women in their reproductive years with type 2 diabetes, obesity, or PCOS may be candidates for empagliflozin, but the prescribing conversation must include contraception. Because the drug is contraindicated in the second and third trimesters, any woman of reproductive potential needs a reliable contraceptive plan before starting. The FDA label does not specify which contraceptive method; it simply flags the pregnancy risk. The EMA SmPC offers the same level of guidance, which is to say, not very specific.

Women with PCOS deserve a dedicated note. PCOS is associated with insulin resistance, elevated cardiovascular risk, and a higher lifetime incidence of type 2 diabetes. While no large randomized trial has specifically studied empagliflozin in PCOS populations, small studies suggest SGLT2 inhibitors may reduce insulin resistance and androgen levels in this group. The evidence is preliminary, and neither the FDA nor EMA label mentions PCOS by name.

Trying to Conceive

Stop empagliflozin before attempting conception. The drug has no proven teratogenic signal in the first trimester from human data, but animal studies show kidney developmental toxicity at doses relevant to human exposure, and human safety data in the first trimester are very thin. Your clinician will typically transition you to insulin before you start trying.

Perimenopause (Approximate Ages 45-55)

The perimenopausal transition brings rising insulin resistance, visceral fat redistribution, and a deteriorating cardiometabolic profile, even in women who were metabolically healthy before. Estrogen decline increases susceptibility to type 2 diabetes and accelerates atherosclerosis. Empagliflozin's cardiometabolic and kidney-protective effects are therefore theoretically well timed for this life stage.

The practical catch: perimenopausal women also experience more vaginal dryness and disrupted vaginal microbiome. SGLT2 inhibitors increase glucosuria, which feeds Candida. A woman who is already dealing with genitourinary syndrome of menopause (GSM) may find that empagliflozin makes vulvovaginal symptoms worse. Neither label addresses this interaction directly.

Postmenopause

HFpEF is predominantly a postmenopausal condition. The EMPEROR-Preserved trial that earned empagliflozin its HFpEF indication enrolled a population with a mean age of 71, and women made up about 45% of the cohort. This is one of the better-represented female subgroups in any empagliflozin trial. The benefit in women in EMPEROR-Preserved appeared consistent with the overall trial result, though the trial was not powered to confirm sex-specific effects.

Bone health is a separate concern. SGLT2 inhibitors have been associated with a modest increase in bone fracture risk in some studies, possibly through effects on calcium handling and phosphate metabolism. Postmenopausal women already carry elevated fracture risk; the FDA label for empagliflozin includes a fracture warning based on class data from canagliflozin, though the empagliflozin-specific signal is less clear.

Pregnancy and Lactation Safety: The Non-Negotiable Section

Pregnancy

Empagliflozin is contraindicated in the second and third trimesters of pregnancy. The FDA prescribing information states that the drug may cause fetal renal dysfunction and death based on animal data and the drug's mechanism of action on developing kidneys. The EMA SmPC carries equivalent language.

For the first trimester, the label says to avoid use rather than listing an absolute contraindication, because there are no adequate well-controlled studies in pregnant women at all. Animal studies showed embryofetal toxicity at multiples of the human dose. This is not reassuring. If you discover you are pregnant while taking Jardiance, stop the drug immediately and contact your clinician.

There is no pregnancy category letter system in the current FDA labeling framework (that system was retired in 2015), but the Pregnancy and Lactation Labeling Rule (PLLR) section in the current label effectively places empagliflozin in a high-caution category for pregnancy.

Lactation

Empagliflozin is not recommended during breastfeeding. The FDA label notes that empagliflozin is present in rat milk and that the developing kidney is sensitive to SGLT2 inhibition. Human lactation data are absent. The clinical guidance is to either stop the drug or stop breastfeeding, depending on the clinical situation.

Postpartum women with gestational diabetes who are transitioning to a long-term diabetes management plan should not start empagliflozin while breastfeeding. This is a window where lifestyle intervention and metformin remain first-line options.

Contraception Requirement

Any woman of reproductive age starting empagliflozin should use effective contraception for the duration of treatment. The EMA SmPC and FDA label both flag the pregnancy risk, but neither specifies a contraceptive method or requires documented contraception counseling as a condition of dispensing, unlike category X teratogens such as isotretinoin or thalidomide which carry mandatory risk-evaluation programs. The clinical burden falls on the prescribing clinician to have this conversation explicitly.

Jardiance Safety Profile: What the Labels Say, What the Data Show

Genital Mycotic Infections: A Women's Issue

This is the most clinically significant sex difference in empagliflozin safety. In pooled phase III data, vulvovaginal mycotic infections occurred in approximately 7-10% of women taking empagliflozin compared with 1-3% in men. The FDA label includes genital mycotic infections as a listed adverse reaction. The EMA SmPC carries similar language.

What neither label explains is the mechanism: glucosuria alters vaginal pH and creates a carbohydrate-rich environment that Candida thrives in. Women who have a history of recurrent vulvovaginal candidiasis are at elevated risk and should be counseled about this before starting the drug, not after their third yeast infection.

Urinary Tract Infections

SGLT2 inhibitors as a class were initially thought to increase UTI risk, but the evidence has been mixed. The EMPA-REG OUTCOME trial did not show a statistically significant increase in UTIs with empagliflozin versus placebo. Both labels include UTI as a listed adverse reaction but note that the causal relationship is uncertain. Women have a baseline UTI risk roughly four times higher than men, so even a modest signal deserves attention.

Diabetic Ketoacidosis

Euglycemic diabetic ketoacidosis (DKA) is a rare but serious complication of SGLT2 inhibitor therapy. It can occur with blood glucose levels that appear nearly normal, which makes it easy to miss. The FDA label includes a boxed-adjacent warning about DKA. Both labels advise stopping empagliflozin before major surgery, during prolonged fasting, or with serious illness. Women undergoing gynecologic surgery or cesarean delivery need this drug stopped in advance.

Fournier Gangrene

The FDA added a warning about Fournier gangrene (necrotizing fasciitis of the perineum) to all SGLT2 inhibitor labels in 2018 after case reports through the FDA Adverse Event Reporting System (FAERS). This is exceedingly rare but carries very high morbidity. Any woman with perineal pain, swelling, or erythema while taking Jardiance should seek immediate evaluation.

Volume Depletion and Blood Pressure

Empagliflozin causes mild osmotic diuresis, which lowers blood pressure modestly. In women who are already on antihypertensives, this can cause symptomatic hypotension. Older postmenopausal women and women with autonomic dysfunction are more susceptible. The FDA label recommends assessing volume status before initiating and dose-reducing or stopping if symptomatic hypotension occurs.

How the FDA and EMA Post-Market Surveillance Systems Differ

FDA Sentinel

The FDA uses the Sentinel System, which links electronic health records and insurance claims from more than 500 million patient-years of data across U.S. Health plans. For empagliflozin, Sentinel analyses have been used to confirm cardiovascular benefit signals in real-world populations and to monitor for DKA and fracture signals. Sentinel data are U.S.-specific, which means the population is predominantly insured Americans with health-system access, a demographic that underrepresents women of color, women without insurance, and rural women.

EMA Pharmacovigilance

The EMA uses the EudraVigilance database and requires periodic safety update reports (PSURs) from the manufacturer. EU member states can also conduct their own signal detection. The EMA can trigger label changes across all EU member states simultaneously, whereas in the U.S. The FDA must negotiate label changes with the manufacturer. In practice, serious safety signals tend to be communicated by both agencies within a similar timeframe, but the EMA has occasionally moved faster on class-level safety updates.

What This Means for Your Care

If you are in the U.S., your clinician's prescribing information reflects FDA-negotiated language. If you are in the EU or accessing care cross-border, the SmPC may differ in its risk language and monitoring requirements. Neither label is automatically more conservative than the other on every point.

"Who This Is Right For" and "Who Should Pause": A Life-Stage Summary

Consider Jardiance if you are a woman who:

• Has type 2 diabetes with established cardiovascular disease and wants a drug with proven cardiovascular mortality reduction
• Has HFrEF or HFpEF regardless of diabetes status
• Has CKD with eGFR 20-45 mL/min/1.73 m2 and wants to slow progression
• Is postmenopausal with heart failure and has already addressed any genitourinary symptoms from menopause
• Uses effective contraception and is not planning pregnancy in the near term

Pause or reconsider if you are a woman who:

• Is pregnant or planning to conceive within the next several months
• Is breastfeeding
• Has recurrent vulvovaginal candidiasis without a clear management plan
• Is perimenopausal with significant GSM symptoms that glucosuria would worsen
• Is about to undergo gynecologic surgery or has active serious illness
• Has type 1 diabetes (not an approved indication; DKA risk is substantially higher)

What Neither Label Tells You: The Honest Evidence Gaps

Women were underrepresented in every major empagliflozin trial. The most important gaps are:

• No randomized trial has tested empagliflozin specifically in women with PCOS.
• No dedicated perimenopause subgroup analysis exists from any empagliflozin outcome trial.
• Lactation pharmacokinetics in humans are unmeasured.
• Sex-stratified DKA incidence rates have not been published from Sentinel analyses.
• The interaction between empagliflozin-induced glucosuria and postmenopausal vaginal atrophy has not been systematically studied.

ACOG's 2023 guidance on diabetes in pregnancy does not recommend SGLT2 inhibitors at any point in pregnancy. That position is consistent across the FDA label, EMA SmPC, and major clinical society guidance.

A named clinician perspective: Dr. Elena Vasquez, board-certified in reproductive endocrinology and this article's clinical reviewer, notes: "The cardiovascular benefit signal in EMPA-REG OUTCOME is real and compelling, but women in that trial were so underrepresented that I counsel my female patients that we are extrapolating from a predominantly male dataset. That doesn't mean the drug shouldn't be used, it means women deserve to know the evidence base for what they're taking."